

# Genetic Control of T-Cell Proliferation with Synthetic RNA Regulatory Systems

Thesis by

Yvonne Yu-Hsuan Chen

In Partial Fulfillment of the Requirements

for the Degree of

Doctor of Philosophy

California Institute of Technology

Pasadena, California

2011

(Defended December 10, 2010)

© 2011

Yvonne Yu-Hsuan Chen

All Rights Reserved

## Acknowledgments

The following pages tell a tale that has been five years in the making. As much as I would like to claim this work for the countless hours spent pipetting alone in tissue culture rooms, singing to Frank Sinatra and Ella Fitzgerald on Pandora Radio, it is in fact the fruit of many individuals' labors. I only hope that the final product has reciprocated some of the efforts given to it by so many.

First, I would like to thank my tireless thesis advisor, Prof. Christina Smolke, for her unfailing support and infinite patience with my research and myself. Even with her abundant talents, Christina is a model of diligence and commitment. I thank her for the thoughtful care she puts into steering this laboratory and guiding its members. Even amidst my most draining experiments, I always had the comfort of knowing that I did not walk alone on this journey.

I must also thank Dr. Michael Jensen for his boundless energy and excitement about my research, his generosity in providing me with resources and advice, and his interest in my professional development. I could not have completed this work without the help of many friends at City of Hope. I thank Araceli Hamlett and Bessie Meechoovet for initiating me into the art of T-cell culturing, Brenda Aguilar for laboring many hours in the animal facility on my behalf, and Cherrilyn Bautista for being my reliable source of expert knowledge on T cells and beyond. I also thank Dr. Christine Brown, Wen-Chung Chang, Michelle Hunter, Renate Starr, Jamie Wagner, and Winnie Wong for being always ready to teach me a technique or lend me a hand. I also must acknowledge Christine Wright for managing the most organized laboratory I have ever seen.

The Smolke Laboratory has been a wonderful home for the past five-and-a-half years. I would like to thank Dr. Chase Beisel and Dr. Stephanie Culler for showing me the ropes in tissue culture and for being so generous with their time and knowledge whenever I had questions or needed advice. I thank Dr. Maun Nyan Win for sharing his expertise on his beloved creation, the ribozyme switch platform. I will always remember Katie Galloway for our stimulating discussions on not-so-scientific subjects, Arwen Brown for sustaining a passion for the humanities in a sea of scientists and engineers, and Leo D’Espaux for his amazing culinary skills and unfettered pursuit of life, even if it leads to a broken bone or two.

Graduate school would not have been nearly as eventful or enjoyable without the many friends I met at Caltech. I thank Arthur Chan, Puneet Chhabra, Claire Farnsworth, and Andrew Metcalf for leading me out of the lab and onto hiking trails. Mike Rubel, Karen Lau, and my cousin Solomon kept me in a semblance of fitness by humoring me on the badminton court. The many hours spent first on transport and thermo problem sets and later on the equally intellectually rigorous game that is Mexican Train with Diana Smirnova, Havala O. T. Pye, and Mary Louie will remain some of my fondest memories of Caltech. Mary, my roommate of three years, kept me sane by being the patient ears for my happy and melancholy ramblings alike. I thank her for showing me a generosity of spirit that I am not sure I knew was possible.

Finally, I would like to thank my most constant supporters—my family. I thank my parents and grandparents for showing me the virtue of perseverance, and for providing a secure and nurturing environment in which to grow. 感謝阿嬤教我謹慎；感謝阿公教我好學；感謝外婆教我努力奮鬥；感謝外公教我在工作之餘不忘生活的

浪漫。爸爸媽媽給我的一切是篇幅再長也述不完的。在這裡只能說聲「實在真多謝。」 And last but certainly not least, I would like to thank my sister, Alice, whose path I seemed destined to follow, at least until now. If the road I traveled has been smoother or more colorful, it is because you have blazed the trail and shown me the way.

**Abstract**

Adoptive T-cell therapy, or the use of autologous T cells to seek and destroy diseased cells, is a promising treatment option for opportunistic diseases, virus-associated malignancies, and cancers. However, the safety and efficacy of adoptive T-cell therapy depend, in part, on the ability to sustain and tightly regulate the proliferation of transferred T cells *in vivo*. The emerging field of synthetic biology provides powerful conceptual and technological tools for the construction of regulatory systems that can interface with and reprogram complex biological processes such as cell growth. Here, we present the development of RNA-based regulatory systems that can control T-cell proliferation in a ligand-dependent manner, and examine the construction of integrated control systems capable of fine-tuned programming of cellular behavior.

We systematically investigate the translation of ribozyme-based regulatory devices from yeast to mammalian cells and identify design parameters critical to the portability of regulatory devices across host organisms. We report the construction of ligand-responsive ribozyme switch systems capable of modulating the transgenic expression of growth-stimulatory cytokines in mammalian lymphocytes. We demonstrate the ability of ribozyme switch systems to regulate T-cell proliferation in primary human central memory T cells and in animal models. We further develop ligand-responsive, miRNA-based devices to regulate the endogenous expression of cytokine receptor chains and the functional output of cytokine signaling pathways, highlighting the ability to construct integrated T-cell proliferation control systems employing various regulatory mechanisms to modulate multiple components in relevant signaling pathways. Finally, we describe efforts in the generation of novel RNA aptamers to clinically suitable

molecules, which can serve as the molecular inputs for ligand-responsive, RNA-based control systems in therapeutic applications.

The regulatory systems developed in this work are designed to be modular and transportable across host organisms and application contexts, thus providing a template for future designs in RNA-based genetic regulation. This work demonstrates the capability of RNA-based regulatory systems to advance next-generation treatment options for critical diseases, and highlights the potential of synthetic biological systems to achieve novel and practical functions in diverse applications.

## Table of Contents

<b>Acknowledgments</b> .....	iii
<b>Abstract</b> .....	vi
<b>Table of Contents</b> .....	viii
<b>List of Tables</b> .....	xi
<b>List of Figures</b> .....	xii
<b>Chapter 1: Introduction</b> .....	I-1
Adoptive T-Cell Therapy: Potentials and Current Limitations.....	I-3
Synthetic Biology: Constructing Novel Devices with Biological Parts.....	I-6
RNA as the Design Substrate for Synthetic Control Devices.....	I-7
Frameworks for Constructing RNA-Based Control Devices.....	I-8
Ligand-Responsive Ribozyme-Based Regulatory Devices.....	I-10
Ligand-Responsive RNAi-Based Regulatory Devices.....	I-13
Aptamers and <i>In Vitro</i> Selection Schemes for Novel Ligand-Binding Sequences.....	I-17
Synthetic RNA-Based Regulatory Systems for T-Cell Proliferation Control...	I-18
Regulatory System Development and Thesis Organization.....	I-19
References.....	I-21
<b>Chapter 2: Translation of Ribozyme-Based Gene Expression Control Devices from Yeast to Mammalian Cells</b> .....	II-1
Abstract.....	II-2
Introduction.....	II-4
Results.....	II-6
Discussion.....	II-18
Materials and Methods.....	II-23
Acknowledgments.....	II-28
References.....	II-28



<b>Chapter 3: T-Cell Proliferation Control with Ribozyme-Based Regulatory Systems.....</b>	III-1
Abstract.....	III-2
Introduction.....	III-3
Results.....	III-4
Discussion.....	III-18
Materials and Methods.....	III-21
Acknowledgments.....	III-34
References.....	III-35
Supplementary Texts.....	III-40
Supplementary Figures.....	III-49
<b>Chapter 4: Proliferation Control of Human Lymphocytes with Ribozyme-Based Regulatory Systems.....</b>	IV-1
Abstract.....	IV-2
Introduction.....	IV-4
Results.....	IV-8
Discussion.....	IV-19
Materials and Methods.....	IV-23
Acknowledgments.....	IV-29
References.....	IV-29
Supplementary Text.....	IV-35
Supplementary Figure.....	IV-35
<b>Chapter 5: T-Cell Proliferation Control with RNAi-Based Regulatory Systems..</b>	V-1
Abstract.....	V-2
Introduction.....	V-4
Results.....	V-7
Discussion.....	V-31
Materials and Methods.....	V-36
Acknowledgments.....	V-42

References.....	V-42
Supplementary Texts.....	V-46
Supplementary Table and Figures.....	V-55
<b>Chapter 6: <i>In Vitro</i> Selection of RNA Aptamers to Clinically Applicable Small-Molecule Ligands.....</b>	<b>VI-1</b>
Abstract.....	VI-2
Introduction.....	VI-3
Results.....	VI-5
Discussion.....	VI-42
Materials and Methods.....	VI-45
Acknowledgments.....	VI-56
References.....	VI-56
<b>Chapter 7: Conclusions.....</b>	<b>VII-1</b>
Immediate Challenges for the Clinical Translation of RNA-Based T-Cell Proliferation Control Systems.....	VII-2
Future Directions for the Development of RNA-Based Regulatory Systems for Clinical Applications.....	VII-5
References.....	VII-9
<b>Appendix 1: Small-Molecule Toxicity Curves in CTLL-2 Cells.....</b>	<b>A1-1</b>
<b>Appendix 2: Small-Molecule Toxicity Curves in NK-92 Cells.....</b>	<b>A2-1</b>

**List of Tables**

- Table 2.1 Theophylline-responsive ribozyme switch activities in yeast and HEK cells
- Table 2.2 Theophylline-responsive ribozyme switch activities in transiently transfected and stably integrated HEK 293 cells
- Table 6.1 Radioactive binding assay for putative vitamin B<sub>12</sub> aptamer sequences with vitamin B<sub>12</sub>-conjugated agarose columns
- Table 6.2 Radioactive binding assay for putative vitamin B<sub>12</sub> aptamer sequences with Sepharose 6B columns
- Table 6.3 Radioactive binding assay for putative folinic acid aptamer sequences with folinic acid-conjugated and unmodified Sepharose 6B columns
- Supplementary Table 5.1 Effects of theophylline on IL-2R $\beta$  and  $\gamma_c$  surface antibody staining intensities in transiently transfected CTLL-2 cells

**List of Figures**

- Figure 1.1 Schematic of CTL-mediated cell lysis
- Figure 1.2 Schematic of adoptive T-cell transfer using either autologous TILs or engineered tumor-targeting T cells
- Figure 1.3 Schematic for a ligand-responsive ribozyme-based ON switch
- Figure 1.4 Schematic for a ligand-responsive shRNA-based ON switch
- Figure 1.5 Schematic for a ligand-responsive miRNA-based ON switch
- Figure 2.1 Ribozyme switches provide tunable, ligand-responsive gene regulation
- Figure 2.2 Ribozyme switch devices are modularly integrated into mammalian expression vectors
- Figure 2.3 Ribozyme switches provide titratable gene regulation
- Figure 2.4 Stably integrated cell lines show tight gene expression distributions and demonstrate long-term regulatory activities by ribozyme switches
- Figure 2.5 Higher-order information-processing devices must be composed of switch components with robust individual performance levels to achieve the prescribed regulatory activity in mammalian cells
- Figure 3.1 An engineered T-cell proliferation regulatory system utilizing a synthetic RNA device to achieve drug-mediated modulation of cell signaling and proliferation
- Figure 3.2 Modularly constructed ribozyme switches exhibit tunable, drug-mediated regulation of gene expression and cell growth in mammalian T cells
- Figure 3.3 Ribozyme switches can be programmed to respond to alternative drug molecules
- Figure 3.4 Ribozyme switches can be programmed to regulate alternative gene targets
- Figure 3.5 The generation of T-cell lines stably expressing the ribozyme switch systems through alternate cycles of negative and positive selections
- Figure 3.6 T cells stably expressing ribozyme switch systems exhibit drug-mediated regulation of growth over extended time periods *in vitro*

- Figure 3.7 T cells stably expressing ribozyme switch systems exhibit drug-mediated regulation of growth over extended time periods *in vivo*
- Figure 4.1 NK-92 cells cannot be effectively transfected by electroporation with DNA plasmids based on the pIL2 expression vector
- Figure 4.2 NK-92 cells cannot be effectively transfected by electroporation with DNA plasmids based on the pcDNA3.1(+) and pcDNA5/FRT expression vectors
- Figure 4.3 Appropriate bacterial strain and purification method used to prepare DNA plasmids are necessary but not sufficient for achieving high transfection efficiency in NK-92 cells
- Figure 4.4 Vector backbone has greater influence on transfection efficiency in NK-92 cells than the specific fluorophore encoded by the vector
- Figure 4.5 A ribozyme switch device is capable of gene expression knockdown in NK-92 cells
- Figure 4.6 The suicide-gene safety switch programmed in ribozyme-based proliferation control systems is functional in primary human T<sub>CM</sub> cells
- Figure 4.7 T<sub>CM</sub> cells stably expressing ribozyme switch systems exhibit the proper phenotype for therapeutic applications
- Figure 4.8 The ribozyme switch system effectively regulates gene expression and cell fate in primary human T<sub>CM</sub> cells
- Figure 5.1 A single-copy miRNA regulated by the Tet-OFF inducible promoter system has lower knockdown efficiency and smaller switch dynamic range compared to a single-copy ligand-responsive miRNA switch construct
- Figure 5.2 Multiple-copy expression of miRNAs improves knockdown efficiency and fold-change in gene expression in response to ligand induction
- Figure 5.3 Multiple-copy expression of IL-2R $\beta$ - and  $\gamma_c$ -targeting miRNAs improves knockdown efficiency
- Figure 5.4 Combinatorial expression of IL-2R $\beta$ - and  $\gamma_c$ -targeting miRNAs achieves effective receptor chain knockdown with high target specificity
- Figure 5.5 Secondary structures of miRNA switches

- Figure 5.6 Secondary structure has substantial impact on miRNA switch dynamic range and knockdown efficiency
- Figure 5.7 Secondary structures of modified miRNA switches based on Bm5 Theo1
- Figure 5.8 Secondary structures of modified miRNA switches based on Bm5 Theo4
- Figure 5.9 Combining features from different miRNA secondary structures exhibiting either strong knockdown efficiency or ligand responsiveness results in improved switch designs
- Figure 5.10 miRNA switches show tunable, theophylline-responsive knockdown of endogenous IL-2R $\beta$  expression levels
- Figure 5.11 miRNA switches show tunable knockdown of endogenous  $\gamma_c$  expression levels
- Figure 5.12 CTLL-2 cells cultured with IL-2 and IL-15 respond differently to treatments with IL-2R $\beta$ - and  $\gamma_c$ -blocking antibodies
- Figure 5.13 miRNA switches regulate functional outputs in the IL-15 signaling pathway
- Figure 6.1 Chemical structure of phenobarbital
- Figure 6.2 Schematic of conventional nitrocellulose membrane-based SELEX for RNA aptamer selection to BSA-conjugated phenobarbital
- Figure 6.3 RNA sequence pools obtained after multiple selection cycles show strong affinity for nitrocellulose membranes and no specific binding for phenobarbital-BSA
- Figure 6.4 Randomized RNA sequence pool has minimal affinity for nitrocellulose membrane
- Figure 6.5 Nitrocellulose membrane-binding RNA sequences are enriched through selection cycles
- Figure 6.6 Removal of nonspecifically bound RNA molecules from nitrocellulose membranes can be achieved with small wash volumes
- Figure 6.7 Nitrocellulose membranes show weak retention of RNA aptamers bound to their specific protein ligands

- Figure 6.8 Schematic of nitrocellulose membrane-based SELEX with ligand-specific elution for the selection of RNA aptamers to BSA-conjugated phenobarbital
- Figure 6.9 RNA sequence pools obtained after multiple selection cycles show no specific binding for phenobarbital-BSA or BSA alone
- Figure 6.10 Sequences obtained after various selection cycles show a rapid decrease in sequence diversity and the early appearance of a dominant sequence
- Figure 6.11 Capillary electrophoresis shows no evidence of ligand binding by putative phenobarbital aptamer sequences
- Figure 6.12 Chemical structures of vitamin B<sub>12</sub> (cyanocobalamin) and folinic acid
- Figure 6.13 The randomized RNA library contains constant regions that form a stable basal stem
- Figure 6.14 Schematic of column-based SELEX used to select for RNA aptamers to vitamin B<sub>12</sub>
- Figure 6.15 Vitamin B<sub>12</sub> SELEX resulted in a diverse sequence pool with several sequence and structural motifs after fifteen selection cycles
- Figure 6.16 Putative vitamin B<sub>12</sub> aptamer sequences show weak binding affinity for vitamin B<sub>12</sub>, strong affinity for vitamin B<sub>12</sub>-conjugated agarose, and no affinity for dihydrazide agarose
- Figure 6.17 Sequence diversity in folinic acid SELEX is dramatically reduced after mutagenic PCR
- Figure 6.18 The putative folinic acid aptamer sequence shows folinic acid-specific binding, no stereospecific binding preference, and strong affinity for the column resin
- Figure 6.19 The putative folinic acid aptamer shows ligand-specific elution
- Figure 6.20 LC-MS and size-exclusion columns can be used to verify binding interactions between RNA aptamers and their cognate small-molecule ligands
- Figure 6.21 The putative folinic acid aptamer shows ligand-specific binding by LC-MS analysis

- Figure 6.22 LC-MS binding assays cannot be performed at high folinic acid concentrations due to errors associated with inefficient membrane filtration
- Figure 6.23 Folinic acid binding to the putative folinic acid aptamer is specific to the RNA sequence
- Figure 6.24 6R-folinic acid SELEX yields a diverse sequence pool with conserved motifs
- 
- Supplementary Figure 3.1 Tunable, small molecule-mediated regulation of gene expression in mammalian cells by ribozyme switches
- Supplementary Figure 3.2 Stable cell lines expressing multiple ribozyme switches exhibit lowered basal level and increased switch dynamic range
- Supplementary Figure 3.3 Clonal CTLL-2 cell lines stably expressing engineered ribozyme switch systems exhibit effective theophylline-responsive growth regulation
- Supplementary Figure 3.4 Cells stably expressing the T-cell proliferation regulatory system exhibit theophylline-responsive increase in IL-15 transcription and signal transduction through the JAK-STAT pathway
- Supplementary Figure 3.5 The clonal cell line 1264-48 exhibits accelerated T-cell proliferation in response to small-molecule input
- Supplementary Figure 3.6 A clonal cell line stably expressing a functional ribozyme-based regulatory system exhibits theophylline-responsive increases in *in vivo* growth rate
- Supplementary Figure 3.7 Plasmid maps of T-cell proliferation constructs
- Supplementary Figure 3.8 Plasmid map of T-cell proliferation constructs expressed from a CMV promoter
- Supplementary Figure 3.9 Stable integrants show partial integration and/or CMV promoter silencing
- Supplementary Figure 3.10 Sorted stable integrants show CMV promoter silencing



- Supplementary Figure 3.11 Bulk cell lines stably expressing ribozyme switch systems exhibit gene expression regulation in response to small-molecule input
- Supplementary Figure 3.12 Bulk cell lines stably expressing ribozyme switch systems show excessively high basal growth levels *in vivo*
- Supplementary Figure 3.13 Bulk cell lines stably expressing ribozyme switch systems are selected for high expression levels *in vivo*
- Supplementary Figure 3.14 Sorted stable integrants show continuous CMV promoter silencing
- Supplementary Figure 3.15 Clonal cell lines stably expressing ribozyme switch systems show stringent OFF-state expression control *in vivo*
- Supplementary Figure 3.16 Clonal cell lines stably expressing ribozyme switch systems lack sufficiently high ON-state expression levels to sustain proliferation *in vivo*
- Supplementary Figure 3.17 The *egfp-t2a-il2* transgene is stably integrated but expressed at low levels in clonal cell lines
- Supplementary Figure 3.18 Appropriate controls demonstrate observed ligand-responsive switch activities are due to specific effects of cytokine withdrawal
- Supplementary Figure 4.1 Different GFP variants show different fluorescence intensities in transiently transfected CTLL-2 cells
- Supplementary Figure 5.1 miRNA sequences capable of effective knockdown of IL-2R $\beta$  and  $\gamma_c$  are identified through screening by transient transfection in CTLL-2 cells
- Supplementary Figure 5.2 Multiple-copy expression reduces gene silencing by individual miRNAs but increases overall knockdown activity toward a shared target gene
- Supplementary Figure 5.3 Secondary structures for non-switch miRNAs
- Supplementary Figure 5.4 IL-15 is capable of sustaining CTLL-2 cell growth at comparable levels as IL-2
- Supplementary Figure 5.5 pSTAT5 levels are dependent on cytokine stimulation

- Supplementary Figure 5.6 The impact of IL-2R $\beta$ - and  $\gamma_c$ -targeting miRNA constructs on CTLL-2 proliferation cannot be evaluated by overall percent viability
- Supplementary Figure 5.7 CTLL-2 cell division cannot be quantitatively evaluated by CFSE staining
- Supplementary Figure 5.8 Plasmid maps of miRNA constructs
- Supplementary Figure 5.9 Maximum transgene expression from the Tet-OFF promoter system requires an optimized input ratio between plasmids encoding for the tetO-CMV promoter and the tet transcriptional activator
- Supplementary Figure 5.10 The tetO-CMV promoter is tightly suppressed by the presence of doxycycline
- Supplementary Figure 5.11 A small input of pCS350 permits gating of transfected populations as well as maximum knockdown efficiency and switch activity by the ptetO-wt miRNA construct
- Supplementary Figure 5.12 Secondary structures for three miRNAs containing the same IL-2R $\beta$ -targeting sequence
- 
- Appendix Figure 1.1 Theophylline toxicity curve in CTLL-2 cells
- Appendix Figure 1.2 Tetracycline toxicity curve in CTLL-2 cells
- Appendix Figure 1.3 Doxycycline toxicity curve in CTLL-2 cells
- Appendix Figure 1.4 Phenobarbital toxicity curve in CTLL-2 cells
- Appendix Figure 1.5 Folinic acid toxicity curve in CTLL-2 cells
- Appendix Figure 1.6 Vitamin B<sub>12</sub> toxicity curve in CTLL-2 cells
- Appendix Figure 1.7 Tamoxifen toxicity curve in CTLL-2 cells
- Appendix Figure 1.8 Methanol toxicity curve in CTLL-2 cells
- Appendix Figure 2.1 Theophylline toxicity curve in NK-92 cells
- Appendix Figure 2.2 Tetracycline toxicity curve in NK-92 cells
- Appendix Figure 2.3 Vitamin B<sub>12</sub> toxicity curve in NK-92 cells

Appendix Figure 2.4 Phenobarbital toxicity curve in NK-92 cells

Appendix Figure 2.5 Folinic acid toxicity curve in NK-92 cells